E Fund Management Co. Ltd. Purchases New Position in Arrowhead Pharmaceuticals, Inc. $ARWR

E Fund Management Co. Ltd. acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 5,841 shares of the biotechnology company’s stock, valued at approximately $476,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ARWR. Royal Bank of Canada boosted its position in Arrowhead Pharmaceuticals by 30.2% in the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock valued at $576,000 after buying an additional 10,496 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the first quarter worth $514,000. Goldman Sachs Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after acquiring an additional 979 shares during the last quarter. Finally, Focus Partners Wealth boosted its holdings in shares of Arrowhead Pharmaceuticals by 1,339.5% during the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after acquiring an additional 15,123 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ARWR shares. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Sanford C. Bernstein lifted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Piper Sandler restated an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Leerink Partners upped their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research note on Wednesday, June 17th. Finally, B. Riley Financial raised their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.33.

Insider Activity

In related news, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares of the company’s stock, valued at $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director owned 31,600 shares in the company, valued at $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $87.47 on Friday. The stock has a market cap of $12.32 billion, a price-to-earnings ratio of -38.88 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $19.82 and a twelve month high of $95.49. The company’s fifty day moving average is $82.59 and its 200 day moving average is $72.77. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm’s revenue for the quarter was up 171.0% on a year-over-year basis. During the same period in the prior year, the business earned ($1.26) earnings per share. Sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.